Zusammenfassung
Vitamin K ist ein fettlösliches Vitamin, das vom menschlichen Organismus nicht synthetisiert werden kann. Das mit der Nahrung aufgenomme oder durch Darmbakterien synthetisierte Vitamin K wird im Jejunum resorbiert und zu einem geringen Teil in der Leber gespeichert. Vitamin K ist ein notwendiger Kofaktor bei der funktionellen Modifikation verschiedener Proteine, die in die Koagulation, Kalziumhomöostase und andere physiologische Prozesse eingebunden sind. Vitamin K ermöglicht die posttranslationale γ-Carboxylierung der Gerinnungsfaktoren II, VII, X, IX, Protein C und Protein S. Orale Antikoagulanzien vom Typ der Vitamin-K-Antagonisten blockieren die enzymatische Aktivität der Vitamin-K-Epoxid-Oxidoreduktase (VKORC1). Innerhalb des Vitamin-K-Zyklus ermöglicht die VKORC1 die Regeneration von Vitamin K.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Berkner KL (2000) The vitamin K-dependent carboxylase. J Nutr 130: 1877–1880
Flockhart DA, O’Kane D, Williams MS et al. (2008) ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 10: 139–150
Geisen C, Watzka M, Sittinger K, Steffens M et al. (2005) VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 94: 773–779
Herman D, Peternel P, Stegnar M et al. (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95:782–787
Marchetti G, Caruso P, Lunghi B et al. (2008) Vitamin K-induced modification of coagulation phenotype in VKORC1 homozygous deficiency. J Thromb Haemost 6: 797–803
Millican EA, Lenzini PA, Milligan PE et al. (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110:151–155
Oldenburg J, Bevans CG, Müller CR et al. (2006) Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 8: 347–353
Oldenburg J, Watzka M, Rost S et al. (2007a) VKORC1: molecular target of coumarins. J Thromb Haemost 5(Suppl1): 1–6
Oldenburg J, Bevans CG, Fregin A et al. (2007b) Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 98: 570–578
Oldenburg J, Marinova M, Müller-Reible C et al. (2008) The vitamin K cycle. Vitam Horm 78: 35–62
Rieder MJ, Reiner AP, Gage BF et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352: 2285–2293
Rost S, Fregin A, Ivaskevicius V et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427: 537–541
Sconce EA, Khan TI, Wynne HA et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329–2233
Takahashi H, Wilkinson GR, Nutescu EA et al. (2006) Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and interpopulation differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16:101–110
Tham LS, Goh BC, Nafziger A et al. (2006) A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80:346–355
U.S. Food and Drug Administration (2007) Questions and Answers on new labelling for Warfarin (marketed as Coumadin). http://www.fda.gov/cder/drug/infopage/warfarin/qa.htm. Cited 03 Feb 2009
Vanakker OM, Martin L, Gheduzzi D et al. (2007) Pseudoxanthoma elasticum-like phenotype with cutis laxa and multiple coagulation factor deficiency represents a separate genetic entity. J Invest Dermatol 127: 581–587
Wu SM, Cheung WF, Frazier D et al. (1991) Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science 254: 1634–6163
Yuan HY, Chen JJ, Lee MT et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and interethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 1745–1751
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Watzka, M., Oldenburg, J. (2010). Vitamin K-Zyklus, VKORC1 und die molekularen Mechanismen der oralen Antikoagulation. In: Pötzsch, B., Madlener, K. (eds) Hämostaseologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01544-1_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-01544-1_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-01543-4
Online ISBN: 978-3-642-01544-1
eBook Packages: Medicine (German Language)